BeiGene
BGNE
#968
Rank
$20.05 B
Marketcap
$181.62
Share price
2.21%
Change (1 day)
3.38%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : $2.39 Billion USD

According to BeiGene 's latest financial reports the company's total liabilities are $2.39 Billion USD. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31$2.26 B13.63%
2022-12-31$1.99 B-16.94%
2021-12-31$2.40 B38.78%
2020-12-31$1.73 B173.14%
2019-12-31$0.63 B27.8%
2018-12-31$0.49 B36.93%
2017-12-31$0.36 B584.7%
2016-12-31$52.9 M24.65%
2015-12-31$42.44 M52.39%
2014-12-31$27.85 M-44.87%
2013-12-31$50.52 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
$12.15 M-99.49%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.85 B-64.39%๐Ÿ‡บ๐Ÿ‡ธ USA